Vitamin D: From Photosynthesis, Metabolism, and Action to Clinical Applications

Endocrinology: Adult and Pediatric

Volumn 1-2, Issue , 2015, Pages 1018-1037.e7

  Bouillon, Roger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84954494921     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-18907-1.00059-7     Document Type: Chapter

References (314)

1. Whistler D. Morbo puerili Anglorum, quem patrio idiomate indigenae vocant. The Rickets. Lugduni Batavorum. 1645:1-13.
2. Glisson F. De Rachitide sive morbo puerili, qui vulgo, London. The Rickets Diciteur. 1650:1-416.
3. Mozolowski W. Jedrzej Sniadecki (1768-1883) on the cure of rickets. Nature 1939, 143:121.
4. Palm T.A. The geographic distribution and etiology of rickets. Practitioner 1890, 45:321-342.
5. O'Riordan J., Bijvoet O. Rickets before the discovery of vitamin D. Bonekey Rep 2014, 8(3):478.
6. Huldshinsky K. Heilung von Rachitis durch künstliche Höhensonne. Dtsch Med Wochenschr 1919, 45:712-713.
7. Chick H.P., Dalyell E.J., Hume E. Studies of rickets in Vienna 1919-1922. Medical Research Council Special Report Series No 77 1923, Medical Research Council, London.
8. Hess A.F., Weinstock M. Antirachitic properties imparted to lettuce and to growing wheat by ultraviolet irradiation. Proc Soc Exp Biol Med 1924, 22:5-6.
9. Mellanby E., Cantag M.D. Experimental investigation on rickets. Lancet 1919, 196:407-412.
10. McCollum E.V., Simmonds N., Pitz W. The relation of unidentified dietary factors, the fat-soluble A and water-soluble B of the diet to the growth promoting properties of milk. J Biol Chem 1916, 27:33-38.
11. McCollum E.V., Simmonds N., Becker J.E. Studies on experimental rickets. XXI. An experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem 1922, 53:293-312.
12. Goldblatt H., Soames K.M. A study of rats on a normal diet irradiated daily by the mercury vapour quartz lamp or kept in darkness. The Biochemical Journal 1923, 17:294-297.
13. Windaus A., Linsert O. Vitamin D1. Ann Chem 1928, 465:148.
14. Steenbock H. The induction of growth promoting and calcifying properties in a ration by exposure to light. Science 1924, 60:224-225.
15. Specker B.L., Tsang R.C., Hollis B.W. Effect of race and diet on human-milk vitamin D and 25-hydroxyvitamin D. American Journal of Diseases of Children 1985, 139:1134-1137.
16. Hollis B.W. Vitamin D requirement during pregnancy and lactation. J Bone Miner Res 2007, 22(suppl 2):V39-V44.
17. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
18. Murphy S.P., Calloway D.H. Nutrient intakes of women in NHANES II, emphasizing trace minerals, fiber, and phytate. Journal of the American Dietetic Association 1986, 86:1366-1372.
19. Wallace T.C., Reider C., Fulgoni V.L. Calcium and vitamin D disparities are related to gender, age, race, household income level, and weight classification but not vegetarian status in the United States: analysis of the NHANES 2001-2008 data set. J Am Coll Nutr 2013, 32:321-330.
20. Brown J., Ignatius A., Amling M., Barvencik F. New perspectives on vitamin D sources in Germany based on a novel mathematical bottom-up model of 25(OH)D serum concentrations. European Journal of Nutrition 2013, 52:1733-1742.
21. Lamberg-Allardt C., Karkkainen M., Seppanen R., Bistrom H. Low serum 25-hydroxyvitamin D concentrations and secondary hyperparathyroidism in middle-aged white strict vegetarians. Am J Clin Nutr 1993, 58:684-689.
22. Norman A.W., Bouillon R., Whiting S.J., Vieth R., Lips P. 13th Workshop consensus for vitamin D nutritional guidelines. J Steroid Biochem Mol Biol 2007, 103:204-205.
23. Food EFSASCo. Scientific Panel on Dietetic Products, Nutrition and Allergies: Tolerable upper intake levels for vitamin D and minerals. 2006.
24. Brouwer-Brolsma E.M., Bischoff-Ferrari H.A., Bouillon R., et al. Vitamin D: Do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe. Osteoporos Int 2013, 24:1567-1577.
25. Bouillon R., Carmeliet G., Verlinden L., et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 2008, 29:726-776.
26. Kelley R.I. RSH/Smith-Lemli-Opitz syndrome: Mutations and metabolic morphogenesis. Am J Hum Genet 1998, 63:322-326.
27. Cunniff C., Kratz L.E., Moser A., Natowicz M.R., Kelley R.I. Clinical and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet 1997, 68:263-269.
28. Rossi M., Federico G., Corso G., et al. Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. Journal of Inherited Metabolic Disease 2005, 28:69-80.
29. Morris J.G. Ineffective vitamin D synthesis in cats is reversed by an inhibitor of 7-dehydrocholestrol-delta7-reductase. J Nutr 1999, 129:903-908.
30. Oliveri B., Zeni S., Lorenzetti M.P., Aguilar G., Mautalen C. Effect of one year residence in Antarctica on bone mineral metabolism and body composition. Eur J Clin Nutr 1999, 53:88-91.
31. Du X., Greenfield H., Fraser D.R., Ge K., Trube A., Wang Y. Vitamin D deficiency and associated factors in adolescent girls in Beijing. Am J Clin Nutr 2001, 74:494-500.
32. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501.
33. van Schoor N.M., Lips P. Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab 2011, 25:671-680.
34. Bassil D., Rahme M., Hoteit M. Fuleihan Gel H. Hypovitaminosis D in the Middle East and North Africa: Prevalence, risk factors and impact on outcomes. Dermato-endocrinology 2013, 5:274-298.
35. Munns C., Zacharin M.R., Rodda C.P., et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: A consensus statement. Med J Aust 2006, 185:268-272.
36. Working group of the Australian and New Zealand Bone and Mineral Society ESoAaOA Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 2005, 182:281-285.
37. Luxwolda M.F., Kuipers R.S., Kema I.P., Dijck-Brouwer D.A., Muskiet F.A. Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/L. Br J Nutr 2012, 108:1557-1561.
38. Bouillon R., Van Schoor N.M., Gielen E., et al. Optimal vitamin D status: A critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab 2013, 98:E1283-E1304.
39. Zhu J., DeLuca H.F., Vitamin D. 25-hydroxylase-four decades of searching, are we there yet?. Arch Biochem Biophys 2012, 523:30-36.
40. Henry H.L. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2011, 25:531-541.
41. Blunt J.W., DeLuca H.F., Schnoes H.K. 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry 1968, 7:3317-3322.
42. Ponchon G., Kennan A.L., DeLuca H.F. "Activation" of vitamin D by the liver. J Clin Invest 1969, 48:2032-2037.
43. Cheng J.B., Levine M.A., Bell N.H., Mangelsdorf D.J., Russell D.W. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004, 101:7711-7715.
44. Al Mutair A.N., Nasrat G.H., Russell D.W. Mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family with severe vitamin D deficiency. J Clin Endocrinol Metab 2012, 97:E2022-E2025.
45. Zhu J.G., Ochalek J.T., Kaufmann M., Jones G., Deluca H.F. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci U S A 2013, 110:15650-15655.
46. Fraser D.R., Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 1970, 228:764-766.
47. Monkawa T., Yoshida T., Wakino S., et al. Molecular cloning of cDNA and genomic DNA for human 25-hydroxyvitamin D3 1 alpha-hydroxylase. Biochem Biophys Res Commun 1997, 239:527-533.
48. Fu G.K., Lin D., Zhang M.Y., et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997, 11:1961-1970.
49. St-Arnaud R., Messerlian S., Moir J.M., Omdahl J.L., Glorieux F.H. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 1997, 12:1552-1559.
50. Takeyama K., Kitanaka S., Sato T., Kobori M., Yanagisawa J., Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997, 277:1827-1830.
51. Shinki T., Shimada H., Wakino S., et al. Cloning and expression of rat 25-hydroxyvitamin D3-1alpha-hydroxylase cDNA. Proc Natl Acad Sci U S A 1997, 94:12920-12925.
52. Overbergh L., Decallonne B., Valckx D., et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 2000, 120:139-146.
53. Jones G., Prosser D.E., Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. Journal of Lipid Research 2014, 55:13-31.
54. Razzaque M.S., Sitara D., Taguchi T., St-Arnaud R., Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006, 20:720-722.
55. Brenza H.L., Kimmel-Jehan C., Jehan F., et al. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci U S A 1998, 95:1387-1391.
56. Murayama A., Takeyama K., Kitanaka S., Kodera Y., Hosoya T., Kato S. The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha,25(OH)2D3. Biochem Biophys Res Commun 1998, 249:11-16.
57. Kato S., Fujiki R., Kim M.S., Kitagawa H. Ligand-induced transrepressive function of VDR requires a chromatin remodeling complex, WINAC. J Steroid Biochem Mol Biol 2007, 103:372-380.
58. Bikle D.D. Vitamin D and the skin. J Bone Miner Metab 2010, 28:117-130.
59. Overbergh L., Stoffels K., Waer M., Verstuyf A., Bouillon R., Mathieu C. Immune regulation of 25-hydroxyvitamin D-1alpha-hydroxylase in human monocytic THP1 cells: Mechanisms of interferon-gamma-mediated induction. J Clin Endocrinol Metab 2006, 91:3566-3574.
60. Fraser D., Kooh S.W., Kind H.P., Holick M.F., Tanaka Y., DeLuca H.F. Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 1973, 289:817-822.
61. Cheung M., Roschger P., Klaushofer K., et al. Cortical and trabecular bone density in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2013, 98:E954-E961.
62. Kitanaka S., Takeyama K., Murayama A., et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998, 338:653-661.
63. Ohyama Y., Noshiro M., Eggertsen G., et al. Structural characterization of the gene encoding rat 25-hydroxyvitamin D3 24-hydroxylase. Biochemistry 1993, 32:76-82.
64. St-Arnaud R., Arabian A., Travers R., et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000, 141:2658-2666.
65. Meyer M.B., Zella L.A., Nerenz R.D., Pike J.W. Characterizing early events associated with the activation of target genes by 1,25-dihydroxyvitamin D3 in mouse kidney and intestine in vivo. J Biol Chem 2007, 282:22344-22352.
66. Schlingmann K.P., Kaufmann M., Weber S., et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011, 365:410-421.
67. Nesterova G., Malicdan M.C., Yasuda K., et al. 1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a cause of nephrolithiasis. Clinical Journal of the American Society of Nephrology: CJASN 2013, 8:649-657.
68. Albertson D.G., Ylstra B., Segraves R., et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000, 25:144-146.
69. Reddy G.S., Siucaldera M.L., Schuster I. E. Target tissue specific metabolism of 1,25(OH)2D3 through A-ring modification. Vitamin D: chemistry, biology and clinical applications of the steroid hormone 1997, 139-146. University of California, Riverside, CA. A. Norman, R. Bouillon, M. Thomasset (Eds.).
70. Wang Z., Lin Y.S., Dickmann L.J., et al. Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: Implications for drug-induced osteomalacia. J Bone Miner Res 2013, 28:1101-1116.
71. Slominski A.T., Kim T.K., Li W., Yi A.K., Postlethwaite A., Tuckey R.C. The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J Steroid Biochem Mol Biol 2014, 144(Pt A:28-39.
72. Dueland S., Pedersen J.I., Helgerud P., Drevon C.A. Absorption, distribution, and transport of vitamin D3 and 25-hydroxyvitamin D3 in the rat. Am J Physiol 1983, 245:E463-E467.
73. Bouillon R., Vanbaelen H., Rombauts W., Demoor P. Purification and characterization of human serum-binding protein for 25-hydroxycholecalciferol (transcalciferin)-Identity with group-specific component. European Journal of Biochemistry 1976, 66:285-291.
74. Hirschfeld J. Immune-electrophoretic demonstration of qualitative differences in human sera and their relation to the haptoglobins. Acta Pathol Microbiol Scand 1959, 47:160-168.
75. Westwood S.A., Werrett D.J. Group-specific component-A review of the isoelectric-focusing methods and auxiliary methods available for the separation of its phenotypes. Forensic Science International 1986, 32:135-150.
76. Cleve H., Constans J. The mutants of the vitamin D-binding protein-More than 120 variants of the GC/DBP system. Vox Sanguinis 1988, 54:215-225.
77. Cooke N.E., Safadi F.F., Magiera H. E. Biological consequences of vitamin D binding protein deficiency in a mouse model. Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone 1997, 105-111. University of California, Riverside (CA). A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
78. Bouillon B. The vitamin D binding protein. Vitamin D 2011, 57-72. Elsevier, London. D. Feldman, J.W. Pike, J. Adams (Eds.).
79. Verboven C., Ragijns A., De Maeyer M., Van Baelen H., Bouillon R., De Ranter C. A structural basis for the unique binding features of the human vitamin D-binding protein. Nature Structural Biology 2002, 9:131-136.
80. Laing C.J., Cooke N. Vitamin D-binding protein. Vitamin D 2005, 117-134. Academic Press. 2nd ed. J.W. Pike, F.H. Glorieux, D. Feldman (Eds.).
81. Bouillon R., Van Baelen H. The transport of vitamin D: Significance of free and total concentrations of vitamin D metabolites. Vitamin D: chemical, biochemical and clinical endocrinology of calcium metabolism 1982, 1181-1186. Walter de Gruyter, Berlin. A.W. Norman, K. Schaefer, D. Von Herrath (Eds.).
82. Vicchio D., Yergey A., O'Brien K., Allen L., Ray R., Holick M. Quantification and kinetics of 25-hydroxyvitamin D3 by isotope dilution liquid chromatography/thermospray mass spectrometry. Biol Mass Spectrom 1993, 22:53-58.
83. Kumar R. The metabolism and mechanism of action of 1,25-dihydroxyvitamin D3. Kidney Int 1986, 30:793-803.
84. Jones K.S., Schoenmakers I., Bluck L.J., Ding S., Prentice A. Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults. Br J Nutr 2012, 107:1128-1137.
85. Bouillon R., Vanassche F.A., Vanbaelen H., Heyns W., Demoor P. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3-Significance of the free 1,25-dihydroxyvitamin D3 concentration. Journal of Clinical Investigation 1981, 67:589-596.
86. Nykjaer A., Dragun D., Walther D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D-3. Cell 1999, 96:507-515.
87. Wang T.J., Zhang F., Richards J.B., et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 2010, 376:180-188.
88. Janssens W., Bouillon R., Claes B., et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010, 65:215-220.
89. Powe C.E., Evans M.K., Wenger J., et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013, 369:1991-2000.
90. McLeod J.F., Kowalski M.A., Haddad J.G. Interactions among serum vitamin D-binding protein, monomeric actin, profilin, and profilactin. Journal of Biological Chemistry 1989, 264:1260-1267.
91. Vanbaelen H., Bouillon R., Demoor P. Vitamin D-binding protein (Gc-globulin) binds actin. Journal of Biological Chemistry 1980, 255:2270-2272.
92. Goldschmidt-Clermont P.J., Vanbaelen H., Bouillon R., et al. Role of group-specific component (vitamin D-binding protein) in clearance of actin from the circulation in the rabbit. Journal of Clinical Investigation 1988, 81:1519-1527.
93. Lee W.M., Galbraith R.M. Mechanisms of disease-The extracellular actin-scavenger system and actin toxicity. New England Journal of Medicine 1992, 326:1335-1341.
94. Haussler M.R., Whitfield G.K., Kaneko I., et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int 2013, 92:77-98.
95. Haussler M.R., Jurutka P.W., Mizwicki M., Norman A.W. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): Genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 2011, 25:543-559.
96. Orlov I., Rochel N., Moras D., Klaholz B.P. Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. The EMBO Journal 2012, 31:291-300.
97. Miyamoto K., Kesterson R.A., Yamamoto H., et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997, 11:1165-1179.
98. Crofts L.A., Hancock M.S., Morrison N.A., Eisman J.A. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci U S A 1998, 95:10529-10534.
99. Masuyama H., Jefcoat S.C., MacDonald P.N. The N-terminal domain of transcription factor IIB is required for direct interaction with the vitamin D receptor and participates in vitamin D-mediated transcription. Mol Endocrinol 1997, 11:218-228.
100. Pike J.W. Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. Mol Cell Endocrinol 2011, 347:3-10.
101. Dasgupta S., Lonard D.M., O'Malley B.W. Nuclear receptor coactivators: Master regulators of human health and disease. Annual Review of Medicine 2014, 65:279-292.
102. Kitagawa H., Fujiki R., Yoshimura K., et al. The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 2003, 113:905-917.
103. Li B., Carey M., Workman J.L. The role of chromatin during transcription. Cell 2007, 128:707-719.
104. Villagra A., Cruzat F., Carvallo L., et al. Chromatin remodeling and transcriptional activity of the bone-specific osteocalcin gene require CCAAT/enhancer-binding protein beta-dependent recruitment of SWI/SNF activity. J Biol Chem 2006, 281:22695-22706.
105. Lavinsky R.M., Jepsen K., Heinzel T., et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998, 95:2920-2925.
106. Li H., Chen J.D. The receptor-associated coactivator 3 activates transcription through CREB-binding protein recruitment and autoregulation. J Biol Chem 1998, 273:5948-5954.
107. Lisse T.S., Adams J.S., Hewison M. Vitamin D and microRNAs in bone. Critical reviews in eukaryotic gene expression 2013, 23:195-214.
108. Pike J.W., Meyer M.B. Fundamentals of vitamin D hormone-regulated gene expression. J Steroid Biochem Mol Biol 2014, 144(Pt A:5-11.
109. Norman A.W., Mizwicki M.T., Norman D.P. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 2004, 3:27-41.
110. Sequeira V.B., Rybchyn M.S., Tongkao-On W., et al. The role of the vitamin D receptor and ERp57 in photoprotection by 1alpha,25-dihydroxyvitamin D3. Mol Endocrinol 2012, 26:574-582.
111. Norman A.W., Bouillon R., Farach-Carson M.C., et al. Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3. J Biol Chem 1993, 268:20022-20030.
112. Song X., Bishop J.E., Okamura W.H., Norman A.W. Stimulation of phosphorylation of mitogen-activated protein kinase by 1alpha,25-dihydroxyvitamin D3 in promyelocytic NB4 leukemia cells: A structure-function study. Endocrinology 1998, 139:457-465.
113. Norman A.W., Okamura W.H., Farach-Carson M.C., et al. Structure-function studies of 1,25-dihydroxyvitamin D3 and the vitamin D endocrine system. 1,25-dihydroxy-pentadeuterio-previtamin D3 (as a 6-s-cis analog) stimulates nongenomic but not genomic biological responses. J Biol Chem 1993, 268:13811-13819.
114. Bergwitz C., Juppner H. FGF23 and syndromes of abnormal renal phosphate handling. Advances in Experimental Medicine and Biology 2012, 728:41-64.
115. Taketani Y., Miyamoto K., Tanaka K., et al. Gene structure and functional analysis of the human Na+/phosphate co-transporter. The Biochemical Journal 1997, 324(Pt 3):927-934.
116. Wasserman R.H. Vitamin D and the intestinal absorption of calcium: A view and overview. Vitamin D 2005, 411-428. Academic Press, San Diego (CA). D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
117. Van Cromphaut S.J., Dewerchin M., Hoenderop J.G., et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. Proc Natl Acad Sci U S A 2001, 98:13324-13329.
118. Feher J.J. Facilitated calcium diffusion by intestinal calcium-binding protein. Am J Physiol 1983, 244:C303-C307.
119. Pannabecker T.L., Chandler J.S., Wasserman R.H. Vitamin-D-dependent transcriptional regulation of the intestinal plasma membrane calcium pump. Biochem Biophys Res Commun 1995, 213:499-505.
120. Yoshizawa T., Handa Y., Uematsu Y., et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997, 16:391-396.
121. Li Y.C., Pirro A.E., Amling M., et al. Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A 1997, 94:9831-9835.
122. Erben R.G., Soegiarto D.W., Weber K., et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 2002, 16:1524-1537.
123. Dardenne O., Prud'homme J., Arabian A., Glorieux F.H., St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001, 142:3135-3141.
124. Panda D.K., Miao D., Tremblay M.L., et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A 2001, 98:7498-7503.
125. Dardenne O., Prud'homme J., Hacking S.A., Glorieux F.H., St-Arnaud R. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). Bone 2003, 32:332-340.
126. Amling M., Priemel M., Holzmann T., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
127. Dardenne O., Prudhomme J., Hacking S.A., Glorieux F.H., St-Arnaud R. Rescue of the pseudo-vitamin D deficiency rickets phenotype of CYP27B1-deficient mice by treatment with 1,25-dihydroxyvitamin D3: Biochemical, histomorphometric, and biomechanical analyses. J Bone Miner Res 2003, 18:637-643.
128. Hoenderop J.G., Dardenne O., Van Abel M., et al. Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice. FASEB J 2002, 16:1398-1406.
129. Li Y.C., Amling M., Pirro A.E., et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998, 139:4391-4396.
130. Rowling M.J., Gliniak C., Welsh J., Fleet J.C. High dietary vitamin D prevents hypocalcemia and osteomalacia in CYP27B1 knockout mice. J Nutr 2007, 137:2608-2615.
131. Song Y., Kato S., Fleet J.C. Vitamin D receptor (VDR) knockout mice reveal VDR-independent regulation of intestinal calcium absorption and ECaC2 and calbindin D9k mRNA. J Nutr 2003, 133:374-380.
132. Balsan S., Garabedian M., Larchet M., et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986, 77:1661-1667.
133. Hochberg Z., Tiosano D., Even L. Calcium therapy for calcitriol-resistant rickets. The Journal of Pediatrics 1992, 121:803-808.
134. Lieben L., Masuyama R., Torrekens S., et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralisation. J Clin Invest 2012, 122:1803-1815.
135. Benn B.S., Ajibade D., Porta A., et al. Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. Endocrinology 2008, 149:3196-3205.
136. Fujita H., Sugimoto K., Inatomi S., et al. Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. Mol Biol Cell 2008, 19:1912-1921.
137. Renkema K.Y., Nijenhuis T., van der Eerden B.C., et al. Hypervitaminosis D mediates compensatory Ca2+ hyperabsorption in TRPV5 knockout mice. J Am Soc Nephrol 2005, 16:3188-3195.
138. Yamamoto Y., Yoshizawa T., Fukuda T., et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology 2013, 154:1008-1020.
139. Lieben L., Carmeliet G. Vitamin D signaling in osteocytes: Effects on bone and mineral homeostasis. Bone 2013, 54:237-243.
140. Eisman J.A., Bouillon R., Vitamin D. Direct effects of vitamin D metabolites on bone: Lessons from genetically modified mice. Bonekey Rep 2014, 3:499.
141. Bouillon R., Suda T., Vitamin D. Calcium and bone homeostasis during evolution. Bonekey Rep 2014, 3:480.
142. Gardiner E.M., Baldock P.A., Thomas G.P., et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 2000, 14(13):1908-1916.
143. Okano T., Tsugawa N., Masuda S., et al. Regulatory activities of 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem Biophys Res Commun 1989, 163:1444-1449.
144. Tilyard M.W., Spears G.F., Thomson J., Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992, 326:357-362.
145. Matsumotoa T., Takanob T., Saitob H., Takahahib F. Vitamin D analogs and bone: Preclinical and clinical studies with eldecalcitol. Bonekey Rep 2014, 3:513.
146. deLuca HF The development of a bone- and parathyroid-specific analog of vitamin D: 2-Methylene-19-Nor-(20S)-1α,25-dihydroxyvitamin D3. Bonekey Rep 2014, 3:514.
147. Bouillon R., Reid I.R. Vitamin D and its metabolites and its analogs in the management of osteoporosis. Osteoporosis in Men 2012, Academic Press, San Diego (CA). 2nd ed. E. Orwoll, J. Bilezikian, D. Vanderschueren (Eds.).
148. Donohue M.M., Demay M.B. Rickets in VDR null mice is secondary to decreased apoptosis of hypertrophic chondrocytes. Endocrinology 2002, 143:3691-3694.
149. Sabbagh Y., Carpenter T.O., Demay M.B. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A 2005, 102:9637-9642.
150. Masuyama R., Stockmans I., Torrekens S., et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006, 116:3150-3159.
151. Naja R.P., Dardenne O., Arabian A. St Arnaud R. Chondrocyte-specific modulation of Cyp27b1 expression supports a role for local synthesis of 1,25-dihydroxyvitamin D3 in growth plate development. Endocrinology 2009, 150:4024-4032.
152. Meir T., Levi R., Lieben L., et al. Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am J Physiol Renal Physiol 2009, 297:F1192-F1198.
153. Cheng Z., Tu C.L., Li A., et al. Endocrine actions of parathyroid Cyp27b1 in the Ca2+ and skeletal homeostasis: Studies of parathyroid-specific knockout mice. J Bone Miner Res 2012, 27:1108. abstract.
154. Quarles L.D. Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease. Experimental Cell Research 2012, 318:1040-1048.
155. Bikle D.D. Vitamin D and the skin: Physiology and pathophysiology. Rev Endocr Metab Disord 2012, 13:3-19.
156. Bikle D.D., Chang S., Crumrine D., et al. 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest Dermatol 2004, 122:984-992.
157. Gilchrest B.A. Sun exposure and vitamin D sufficiency. Am J Clin Nutr 2008, 88:570S-577S.
158. De Haes P., Garmyn M., Verstuyf A., et al. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol B 2005, 78:141-148.
159. Gupta R., Dixon K.M., Deo S.S., et al. Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. J Invest Dermatol 2007, 127:707-715.
160. Dixon K.M., Norman A.W., Sequeira V.B., et al. 1alpha,25(OH)-vitamin D and a nongenomic vitamin D analogue inhibit ultraviolet radiation-induced skin carcinogenesis. Cancer Prev Res (Phila) 2011, 4:1485-1494.
161. Jensen S.S., Madsen M.W., Lukas J., Binderup L., Bartek J. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 2001, 15:1370-1380.
162. Colston K., Colston M.J., Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 1981, 108:1083-1086.
163. Abe E., Miyaura C., Sakagami H., et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1981, 78:4990-4994.
164. Verlinden L., Eelen G., Beullens I., et al. Characterization of the condensin component Cnap1 and protein kinase Melk as novel E2F target genes down-regulated by 1,25-dihydroxyvitamin D3. J Biol Chem 2005, 280:37319-37330.
165. Moreno J., Krishnan A.V., Peehl D.M., Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: Inhibition of the prostaglandin pathway. Anticancer Res 2006, 26:2525-2530.
166. Aguilera O., Pena C., Garcia J.M., et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 2007, 28:1877-1884.
167. Tong W.M., Kallay E., Hofer H., et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. European Journal of Cancer 1998, 34:2119-2125.
168. Vink-van Wijngaarden T., Pols H.A., Buurman C.J., Birkenhager J.C., van Leeuwen J.P. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. European Journal of Cancer 1996, 32A:842-848.
169. Verlinden L., Verstuyf A., Convents R., Marcelis S., Van Camp M., Bouillon R. Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 1998, 142:57-65.
170. Reitsma P.H., Rothberg P.G., Astrin S.M., et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 1983, 306:492-494.
171. Matsumoto K., Hashimoto K., Nishida Y., Hashiro M., Yoshikawa K. Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun 1990, 166:916-923.
172. Vanoirbeek E., Krishnan A., Eelen G., et al. The anti-cancer and anti-inflammatory actions of 1,25(OH)D. Best Pract Res Clin Endocrinol Metab 2011, 25:593-604.
173. Pereira F., Larriba M.J., Munoz A. Vitamin D and colon cancer. Endocrine-related cancer 2012, 19:R51-R71.
174. Welsh J. Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res 2007, 22(suppl 2):V86-V90.
175. Bouillon R., Eelen G., Verlinden L., Mathieu C., Carmeliet G., Verstuyf A. Vitamin D and cancer. J Steroid Biochem Mol Biol 2006, 102:156-162.
176. Chung M., Lee J., Terasawa T., Lau J., Trikalinos T.A. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: An updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2012, 155:827-838.
177. Giovannucci E. Epidemiology of vitamin D and colorectal cancer. Anti-Cancer Agents in Medicinal Chemistry 2013, 13:11-19.
178. Freedman D.M., Looker A.C., Chang S.C., Graubard B.I. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007, 99:1594-1602.
179. Bouillon R., Bischoff-Ferrari H., Willett W. Vitamin D and health: Perspectives from mice and man. J Bone Miner Res 2008, 23:974-979.
180. Wactawski-Wende J., Kotchen J.M., Anderson G.L., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354:684-696.
181. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr 2007, 85:1586-1591.
182. Stoffels K., Overbergh L., Bouillon R., Mathieu C. Immune regulation of 1alpha-hydroxylase in murine peritoneal macrophages: Unravelling the IFNgamma pathway. J Steroid Biochem Mol Biol 2007, 103:567-571.
183. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
184. Kankova M., Luini W., Pedrazzoni M., et al. Impairment of cytokine production in mice fed a vitamin D3-deficient diet. Immunology 1991, 73:466-471.
185. Giulietti A., Gysemans C., Stoffels K., et al. Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice. Diabetologia 2004, 47:451-462.
186. Davies P.D., Brown R.C., Woodhead J.S. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax 1985, 40:187-190.
187. Grange J.M., Davies P.D., Brown R.C., Woodhead J.S., Kardjito T. A study of vitamin D levels in Indonesian patients with untreated pulmonary tuberculosis. Tubercle 1985, 66:187-191.
188. Waters W.R., Palmer M.V., Nonnecke B.J., Whipple D.L., Horst R.L. Mycobacterium bovis infection of vitamin D-deficient NOS2-/- mice. Microbial Pathogenesis 2004, 36:11-17.
189. Wilkinson R.J., Llewelyn M., Toossi Z., et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: A case-control study. Lancet 2000, 355:618-621.
190. Martineau A.R., Nhamoyebonde S., Oni T., et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 2011, 108:19013-19017.
191. Martineau A.R., Timms P.M., Bothamley G.H., et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: A double-blind randomised controlled trial. Lancet 2011, 377:242-250.
192. Lehouck A., Mathieu C., Carremans C., et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012, 156:105-114.
193. Camargo C.A., Ganmaa D., Frazier A.L., et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics 2012, 130:e561-e567.
194. Manaseki-Holland S., Maroof Z., Bruce J., et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: A randomised controlled superiority trial. Lancet 2012, 379:1419-1427.
195. Bouillon B., Lieben L., Mathieu C., Verstuyf A., Carmeliet G. Vitamin D action: Lessons from VDR and Cyp27b1 null mice. Pediatric Rev Endocrinol 2013, 10(suppl 2):354-366.
196. Zella J.B., DeLuca H.F. Vitamin D and autoimmune diabetes. J Cell Biochem 2003, 88:216-222.
197. Liu N., Nguyen L., Chun R.F., et al. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 2008, 149:4799-4808.
198. Mathieu C., Gysemans C., Giulietti A., Bouillon R. Vitamin D and diabetes. Diabetologia 2005, 48:1247-1257.
199. Guo S.W., Magnuson V.L., Schiller J.J., Wang X., Wu Y., Ghosh S. Meta-analysis of vitamin D receptor polymorphisms and type 1 diabetes: A HuGE review of genetic association studies. Am J Epidemiol 2006, 164:711-724.
200. Bailey R., Cooper J.D., Zeitels L., et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 2007, 56:2616-2621.
201. Cooper J.D., Smyth D.J., Walker N.M., et al. Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 2011, 60:1624-1631.
202. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
203. Yu S., Cantorna M.T. The vitamin D receptor is required for iNKT cell development. Proc Natl Acad Sci U S A 2008, 105:5207-5212.
204. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
205. Leu M., Giovannucci E., Vitamin D. epidemiology of cardiovascular risks and events. Best Pract Res Clin Endocrinol Metab 2011, 25:633-646.
206. Witham M.D., Nadir M.A., Struthers A.D. Effect of vitamin D on blood pressure: A systematic review and meta-analysis. J Hypertens 2009, 27:1948-1954.
207. Aihara K., Azuma H., Akaike M., et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004, 279:35798-35802.
208. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
209. Wang L., Song Y., Manson J.E., et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. Circulation Cardiovascular Quality and Outcomes 2012, 5:819-829.
210. Elamin M.B., Abu Elnour N.O., Elamin K.B., et al. Vitamin D and cardiovascular outcomes: A systematic review and meta-analysis. J Clin Endocrinol Metab 2011, 96:1931-1942.
211. Jorde R., Sneve M., Torjesen P., Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. Journal of Internal Medicine 2010, 267:462-472.
212. Thadhani R., Appelbaum E., Pritchett Y., et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 2012, 307:674-684.
213. Bouillon R., Verstuyf A., Vitamin D. mitochondria, and muscle. J Clin Endocrinol Metab 2013, 98:961-963.
214. Endo I., Inoue D., Mitsui T., et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003, 144:5138-5144.
215. Rosen C.J., Adams J.S., Bikle D.D., et al. The nonskeletal effects of vitamin D: An Endocrine Society scientific statement. Endocr Rev 2012, 33:456-492.
216. Bischoff-Ferrari H.A. Relevance of vitamin D in muscle health. Rev Endocr Metab Disord 2012, 13:71-77.
217. Bischoff-Ferrari H.A., Dawson-Hughes B., Baron J.A., et al. Calcium intake and hip fracture risk in men and women: A meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr 2007, 86:1780-1790.
218. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., et al. Effect of Vitamin D on falls: A meta-analysis. JAMA 2004, 291:1999-2006.
219. Norman A.W., Frankel J.B., Heldt A.M., Grodsky G.M. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980, 209:823-825.
220. Nyomba B.L., Bouillon R., De Moor P. Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology 1984, 115:191-197.
221. Narvaez C.J., Matthews D., Broun E., Chan M., Welsh J. Lean phenotype and resistance to diet-induced obesity in vitamin D receptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. Endocrinology 2009, 150:651-661.
222. Bouillon R., Carmeliet G., Lieben L., et al. Vitamin D and energy homeostasis in mice and men. Nat Rev Endocrinol 2014, 10(2):79-87.
223. Hypponen E., Boucher B.J., Berry D.J., Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008, 57:298-305.
224. Forouhi N.G., Luan J., Cooper A., Boucher B.J., Wareham N.J. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008, 57:2619-2625.
225. Vimaleswaran K.S., Berry D.J., Lu C., et al. Causal relationship between obesity and vitamin D status: Bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Medicine 2013, 10. e1001383.
226. Davidson M.B., Duran P., Lee M.L., Friedman T.C. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 2013, 36:260-266.
227. Welsh J., Zinser L.N., Mianecki-Morton L., et al. Age-related changes in the epithelial and stromal compartments of the mammary gland in normocalcemic mice lacking the vitamin D3 receptor. PLoS One 2011, 6. e16479.
228. Blomberg Jensen M., Lieben L., Nielsen J.E., et al. Characterization of the testicular, epididymal and endocrine phenotypes in the Leuven Vdr-deficient mouse model: Targeting estrogen signalling. Mol Cell Endocrinol 2013, 377:93-102.
229. Dobnig H., Pilz S., Scharnagl H., et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008, 168:1340-1349.
230. Melamed M.L., Michos E.D., Post W., Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168:1629-1637.
231. Rejnmark L., Avenell A., Masud T., et al. Vitamin D with calcium reduces mortality: Patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab 2012, 97:2670-2681.
232. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72:1004-1013.
233. Porteous C.E., Coldwell R.D., Trafford D.J., Makin H.L. Recent developments in the measurement of vitamin D and its metabolites in human body fluids. Journal of Steroid Biochemistry 1987, 28:785-801.
234. Schmidt-Gayk H., Bouillon R., Roth H.J. Measurement of vitamin D and its metabolites (calcidiol and calcitriol) and their clinical significance. Scandinavian Journal of Clinical and Laboratory Investigation Supplementum 1997, 227:35-45.
235. Luxwolda M.F., Kuipers R.S., Kema I.P., van der Veer E., Dijck-Brouwer D.A., Muskiet F.A. Vitamin D status indicators in indigenous populations in East Africa. European Journal of Nutrition 2013, 52:1115-1125.
236. Bouillon R. Radiochemical assays for vitamin D metabolites: Technical possibilities and clinical applications. Journal of Steroid Biochemistry 1983, 19:921-927.
237. Bouillon R., Van Baelen H. Transport of vitamin D: Significance of free and total concentrations of the vitamin D metabolites. Calcif Tissue Int 1981, 33:451-453.
238. Bikle D.D., Gee E. Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology 1989, 124:649-654.
239. Vanham G., Van Baelen H., Tan B.K., Bouillon R. The effect of vitamin D analogs and of vitamin D-binding protein on lymphocyte proliferation. Journal of Steroid Biochemistry 1988, 29:381-386.
240. Bouillon R., Van Baelen H. The transport of vitamin D. Vitamin D Basic Research and Its Clinical Application 1979, 137-143. Walter De Gruyter, Berlin. A.W. Norman, K. Schaefer, D. Von Herrath (Eds.).
241. Vanderschueren D., Pye S.R., O'Neill T.W., et al. Active vitamin D (1,25-dihydroxyvitamin D) and bone health in middle aged and elderly men: The European Male Aging Study (EMAS). J Clin Endocrinol Metab 2013, 98:995-1005.
242. Binkley N., Krueger D., Gemar D., Drezner M.K. Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 2008, 93:1804-1808.
243. Lips P., Chapuy M.C., Dawson-Hughes B., Pols H.A., Holick M.F. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999, 9:394-397.
244. Ong L., Saw S., Sahabdeen N.B., Tey K.T., Ho C.S., Sethi S.K. Current 25-hydroxyvitamin D assays: Do they pass the test?. Clin Chim Acta 2012, 413:1127-1134.
245. de la Hunty A., Wallace A.M., Gibson S., Viljakainen H., Lamberg-Allardt C., Ashwell M. UK Food Standards Agency Workshop Consensus Report: the choice of method for measuring 25-hydroxyvitamin D to estimate vitamin D status for the UK National Diet and Nutrition Survey. Br J Nutr 2010, 104:612-619.
246. Casetta B., Jans I., Billen J., Vanderschueren D., Bouillon R. Development of a method for the quantification of 1alpha,25(OH)2-vitamin D3 in serum by liquid chromatography tandem mass spectrometry without derivatization. European Journal of Mass Spectrometry 2010, 16:81-89.
247. Pettifor J.M., Prentice A. The role of vitamin D in paediatric bone health. Best Pract Res Clin Endocrinol Metab 2011, 25:573-584.
248. Lerch C., Meissner T. Interventions for the prevention of nutritional rickets in term born children. Cochrane Database Syst Rev 2007, CD006164.
249. Beser E., Cakmakci T. Factors affecting the morbidity of vitamin D deficiency rickets and primary protection. East African Medical Journal 1994, 71:358-362.
250. Wagner C.L., Greer F.R. American Academy of Pediatrics Section on B, American Academy of Pediatrics Committee on N. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008, 122:1142-1152.
251. Baroncelli G.I., Bereket A., El Kholy M., et al. Rickets in the Middle East: Role of environment and genetic predisposition. J Clin Endocrinol Metab 2008, 93:1743-1750.
252. van der Meer I.M., Karamali N.S., Boeke A.J., et al. High prevalence of vitamin D deficiency in pregnant non-Western women in The Hague, Netherlands. Am J Clin Nutr 2006, 84:350-353. quiz 468-469.
253. Javaid M.K., Crozier S.R., Harvey N.C., et al. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: A longitudinal study. Lancet 2006, 367:36-43.
254. Harvey N.C., Sheppard A., Godfrey K.M., et al. Childhood bone mineral content is associated with methylation status of the RXRA promoter at birth. J Bone Miner Res 2013.
255. Malabanan A., Veronikis I.E., Holick M.F. Redefining vitamin D insufficiency. Lancet 1998, 351:805-806.
256. Heaney R.P., Dowell M.S., Hale C.A., Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003, 22:142-146.
257. Heaney R.P. The case for improving vitamin D status. J Steroid Biochem Mol Biol 2007, 103:635-641.
258. Need A.G., O'Loughlin P.D., Morris H.A., Coates P.S., Horowitz M., Nordin B.E. Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res 2008, 23:1859-1863.
259. Abrams S.A., Griffin I.J., Hawthorne K.M., Gunn S.K., Gundberg C.M., Carpenter T.O. Relationships among vitamin D levels, parathyroid hormone, and calcium absorption in young adolescents. J Clin Endocrinol Metab 2005, 90:5576-5581.
260. Zhu K., Bruce D., Austin N., Devine A., Ebeling P.R., Prince R.L. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J Bone Miner Res 2008, 23:1343-1348.
261. Hansen K.E., Jones A.N., Lindstrom M.J., Davis L.A., Engelke J.A., Shafer M.M. Vitamin D insufficiency: Disease or no disease?. J Bone Miner Res 2008, 23:1052-1060.
262. Ooms M.E., Lips P., Roos J.C., et al. Vitamin D status and sex hormone binding globulin: Determinants of bone turnover and bone mineral density in elderly women. J Bone Miner Res 1995, 10:1177-1184.
263. Cauley J.A., Lacroix A.Z., Wu L., et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008, 149:242-250.
264. Bischoff-Ferrari H.A., Willett W.C., Orav E.J., et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012, 367:40-49.
265. Boonen S., Lips P., Bouillon R., Bischoff-Ferrari H.A., Vanderschueren D., Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: Evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007, 92:1415-1423.
266. Reid I.R., Bolland M.J., Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int 2008, 19:1119-1123.
267. Bischoff-Ferrari H.A., Rees J.R., Grau M.V., Barry E., Gui J., Baron J.A. Effect of calcium supplementation on fracture risk: A double-blind randomized controlled trial. Am J Clin Nutr 2008, 87:1945-1951.
268. Heaney R.P., Armas L.A., Shary J.R., Bell N.H., Binkley N., Hollis B.W. 25-Hydroxylation of vitamin D3: Relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008, 87:1738-1742.
269. Institute of Medicine (IOM) Dietary reference intake for calcium and vitamin D 2011, National Academies Press, Washignton DC.
270. Rosen C.J., Abrams S.A., Aloia J.F., et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 2012, 97:1146-1152.
271. Roux C., Bischoff-Ferrari H.A., Papapoulos S.E., de Papp A.E., West J.A., Bouillon R. New insights into the role of vitamin D and calcium in osteoporosis management: An expert roundtable discussion. Curr Med Res Opin 2008, 24:1363-1370.
272. Gallagher J.C., Sai A., Templin T., Smith L. Dose response to vitamin D supplementation in postmenopausal women: A randomized trial. Ann Intern Med 2012, 156:425-437.
273. Gallagher J.C., Jindal P.S., Smith L.M. Vitamin d supplementation in young white and African American women. J Bone Miner Res 2014, 29:173-181.
274. Smith H., Anderson F., Raphael H., et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology 2007, 46(12):1852-1857.
275. Chel V., Wijnhoven H.A., Smit J.H., Ooms M., Lips P. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int 2008, 19:663-671.
276. Clements M.R., Johnson L., Fraser D.R. A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature 1987, 325:62-65.
277. Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res 2007, 22(suppl 2):V64-V68.
278. Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science 2012, 337:1476-1478.
279. Hagenau T., Vest R., Gissel T.N., et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: An ecologic meta-regression analysis. Osteoporos Int 2009, 20:133-140.
280. Chapuy M.C., Preziosi P., Maamer M., et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997, 7:439-443.
281. van der Wielen R.P., Lowik M.R., van den Berg H., et al. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995, 346:207-210.
282. Lips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 2007, 103:620-625.
283. Ganji V., Zhang X., Tangpricha V. Serum 25-hydroxyvitamin D concentrations and prevalence estimates of hypovitaminosis D in the U.S. population based on assay-adjusted data. J Nutr 2012, 142:498-507.
284. Cawthon P.M., Parimi N., Barrett-Connor E., et al. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. J Clin Endocrinol Metab 2010, 95:4625-4634.
285. Lee D.M., Tajar A., Pye S.R., et al. Association of hypogonadism with vitamin D status: The European Male Ageing Study. Eur J Endocrinol 2012, 166:77-85.
286. Rahman S.A., Chee W.S., Yassin Z., Chan S.P. Vitamin D status among postmenopausal Malaysian women. Asia Pacific Journal of Clinical Nutrition 2004, 13:255-260.
287. Fraser D.R. Vitamin D-deficiency in Asia. J Steroid Biochem Mol Biol 2004, 89-90:491-495.
288. Uush T. Prevalence of classic signs and symptoms of rickets and vitamin D deficiency in Mongolian children and women. J Steroid Biochem Mol Biol 2013, 136:207-210.
289. Bouillon R., Norman A.W., Lips P. Vitamin D deficiency. N Engl J Med 2007, 357:1980-1981. author reply 1-2.
290. Norman A.W., Bouillon R. Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood) 2010, 235:1034-1045.
291. Bouillon R., Garmyn M., Verstuyf A., Segaert S., Casteels K., Mathieu C. Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs. Eur J Endocrinol 1995, 133:7-16.
292. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995, 16:200-257.
293. Eelen G., Gysemans C., Verlinden L., et al. Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Current Medicinal Chemistry 2007, 14:1893-1910.
294. Verstuyf A., Verlinden L., Van Baelen H., et al. The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings. J Bone Miner Res 1998, 13:549-558.
295. Eelen G., Valle N., Sato Y., et al. Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. Chemistry & Biology 2008, 15:1029-1034.
296. Liu Y.Y., Collins E.D., Norman A.W., Peleg S. Differential interaction of 1alpha,25-dihydroxyvitamin D3 analogues and their 20-epi homologues with the vitamin D receptor. J Biol Chem 1997, 272:3336-3345.
297. van den Bemd G.C., Pols H.A., Birkenhager J.C., van Leeuwen J.P. Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060. Proc Natl Acad Sci U S A 1996, 93:10685-10690.
298. Rochel N., Wurtz J.M., Mitschler A., Klaholz B., Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Molecular Cell 2000, 5:173-179.
299. Bouillon R., Allewaert K., Xiang D.Z., Tan B.K., van Baelen H. Vitamin D analogs with low affinity for the vitamin D binding protein: Enhanced in vitro and decreased in vivo activity. J Bone Miner Res 1991, 6:1051-1057.
300. De Clercq P.J., De Buysser F., Minne G., et al. The development of CD-ring modified analogs of 1alpha,25-dihydroxyvitamin D. J Steroid Biochem Mol Biol 2007, 103:206-212.
301. Matsumoto T., Miki T., Hagino H., et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2005, 90:5031-5036.
302. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349:446-456.
303. Bikle D.D., Pillai S., Vitamin D. calcium, and epidermal differentiation. Endocr Rev 1993, 14:3-19.
304. Fogh K., Kragballe K. Vitamin D3 analogues. Clinics in dermatology 1997, 15:705-713.
305. van de Kerkhof P.C. Reduction of epidermal abnormalities and inflammatory changes in psoriatic plaques during treatment with vitamin D3 analogs. The Journal of Investigative Dermatology Symposium Proceedings / the Society for Investigative Dermatology. Inc [and] European Society for Dermatological Research 1996, 1:78-81.
306. Lu I., Gilleaudeau P., McLane J.A., et al. Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infilitration in psoriatic plaques by topical calcitriol. Journal of Cutaneous Pathology 1996, 23:419-430.
307. Beer T.M., Eilers K.M., Garzotto M., Egorin M.J., Lowe B.A., Henner W.D. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003, 21:123-128.
308. Ma Y., Yu W.D., Hidalgo A.A., et al. Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle 2013, 12:743-752.
309. van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol 2005, 97:93-101.
310. Baeke F., Van Belle T.L., Takiishi T., et al. Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes. Diabetologia 2012, 55:2723-2732.
311. White J.H. Regulation of intracrine production of 1,25-dihydroxyvitamin D and its role in innate immune defense against infection. Arch Biochem Biophys 2012, 523:58-63.
312. Adorini L., Penna G., Amuchastegui S., et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007, 103:689-693.
313. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005, 16:713-716.
314. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.